弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是非霍奇金淋巴瘤最常见的类型,相对于霍奇金淋巴瘤,更易发生淋巴结外侵犯和远处转移;尽管DLBCL可累及全身任何部位,但主要发生于腹膜后的情况极少见^([1-3])。DLBCL的临床表现...弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是非霍奇金淋巴瘤最常见的类型,相对于霍奇金淋巴瘤,更易发生淋巴结外侵犯和远处转移;尽管DLBCL可累及全身任何部位,但主要发生于腹膜后的情况极少见^([1-3])。DLBCL的临床表现缺乏特异性,因主要侵犯部位不同而呈现不同的临床症状,易误导临床医师对疾病的判断,尤其是当淋巴瘤侵犯腹膜后等少见部位时。腹膜后淋巴瘤可侵犯胰腺,临床表现酷似急性胰腺炎;随着疾病的进展,肿瘤组织逐渐融合呈片状软组织肿块,与腹膜后纤维化这一临床少见疾病难以鉴别^([4]),易致相互误诊。本文报道南昌大学江西医学院第一附属医院消化内科收治的1例以“急性胰腺炎”起病,之后发展为类似“腹膜后纤维化”改变,最终确诊为“弥漫大B细胞淋巴瘤”病例的诊治经过,以期提高临床医师对类似情况的认知和处理水平。展开更多
We report the case of a patient affected by an extra-nodal non-Hodgkin lymphoma presenting as a unique, large retroperitoneal mass with an unusual clinical presentation mimicking gastric peptic or neoplastic disease. ...We report the case of a patient affected by an extra-nodal non-Hodgkin lymphoma presenting as a unique, large retroperitoneal mass with an unusual clinical presentation mimicking gastric peptic or neoplastic disease. The patientwas successfully treated with a first generation therapy,CHOP modified regimen (cyclophosphamide 600mg/m^2 intravenously on d 1, epirubicin 55mg/m^2 intravenously on d 1, vincristine 1.2 mg/m^2 intravenously on d 1,prednisone 60 mg/m^2 on d 1-5), and a complete response was achieved. The (18)F-fluorodeoxyglucose positron emission tomography was used to assess the therapy outcome. A brief review of literature is provided.展开更多
文摘弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是非霍奇金淋巴瘤最常见的类型,相对于霍奇金淋巴瘤,更易发生淋巴结外侵犯和远处转移;尽管DLBCL可累及全身任何部位,但主要发生于腹膜后的情况极少见^([1-3])。DLBCL的临床表现缺乏特异性,因主要侵犯部位不同而呈现不同的临床症状,易误导临床医师对疾病的判断,尤其是当淋巴瘤侵犯腹膜后等少见部位时。腹膜后淋巴瘤可侵犯胰腺,临床表现酷似急性胰腺炎;随着疾病的进展,肿瘤组织逐渐融合呈片状软组织肿块,与腹膜后纤维化这一临床少见疾病难以鉴别^([4]),易致相互误诊。本文报道南昌大学江西医学院第一附属医院消化内科收治的1例以“急性胰腺炎”起病,之后发展为类似“腹膜后纤维化”改变,最终确诊为“弥漫大B细胞淋巴瘤”病例的诊治经过,以期提高临床医师对类似情况的认知和处理水平。
文摘We report the case of a patient affected by an extra-nodal non-Hodgkin lymphoma presenting as a unique, large retroperitoneal mass with an unusual clinical presentation mimicking gastric peptic or neoplastic disease. The patientwas successfully treated with a first generation therapy,CHOP modified regimen (cyclophosphamide 600mg/m^2 intravenously on d 1, epirubicin 55mg/m^2 intravenously on d 1, vincristine 1.2 mg/m^2 intravenously on d 1,prednisone 60 mg/m^2 on d 1-5), and a complete response was achieved. The (18)F-fluorodeoxyglucose positron emission tomography was used to assess the therapy outcome. A brief review of literature is provided.
